DUNDEE, Scotland and MONTREAL, May 22, 2017 /CNW Telbec/ - University of Dundee, its Drug Discovery Unit ("DDU"), and Corbin Therapeutics ("Corbin") are pleased to announce their collaboration agreement to screen and identify small molecules capable of efficiently inhibiting a well-conserved ubiquitin-specific protease, USP15.
Corbin focuses on a novel therapeutic approach to treat various inflammatory disorders via USP15 inhibition. Recently published in Nature Immunology [(2017) 18:54–63], this protease is central in the neuro-inflammation pathology and its inhibition might be key preventing and treating inflammatory-based diseases, such as multiple sclerosis.
DDU has expanded its drug discovery capabilities towards a unique collaborative model, which maximizes the translation of life sciences research into therapeutic applications. The DDU works with partners across a wide variety of disciplines, including high-throughput screening, DMPK, medicinal chemistry, bioinformatics and computational drug design.
Dr. Maxime Ranger, President and Chief Executive Officer of Corbin, commented, "We are very pleased to make this alliance with DDU, where both combine their complementary expertise into novel target validation and efforts to identify promising inhibitors of USP15." Professor Paul Wyatt, Head of the DDU, added, "The DDU is committed to working collaboratively with partners, such as Corbin, to develop potential drug targets for diseases of unmet clinical need. We look forward to developing a productive partnership on this exciting target"
About Corbin Therapeutics
Corbin Therapeutics (www.corbinthera.com) is a Montreal-based biotechnology company, using a unique drug discovery platform to identify and develop novel USP15 inhibitors for treatment of various inflammation diseases, such as multiple sclerosis. This platform includes several in-vitro and in-vivo models for efficient drug screening and confirmation of potential lead candidates.
The Drug Discovery Unit (DDU) (www.drugdiscovery.dundee.ac.uk) is a fully integrated drug discovery operation based within a world class Life Sciences research environment. Its remit is to tackle both neglected diseases (trypanosomiasis, leishmaniasis and malaria) and early stage small molecule validation of novel targets & mechanisms across a range of potential therapeutic areas. The project goals are therapeutic area dependent but range from quality leads demonstrating disease model proof of concept, through to pre-clinical candidates.
SOURCE Corbin Therapeutics inc
For further information: Contacts for Media: Dr. Maxime Ranger, CEO, Corbin Therapeutics, +1.514.825.9035, firstname.lastname@example.org; Professor Paul Wyatt FRSE, Head of the Drug Discovery Unit, University of Dundee, email@example.com